Combination of Abiraterone Acetate, Prostate Bed Radiotherapy, and Luteinizing Hormone-releasing Hormone Agonists in Biochemically Relapsing Patients After Prostatectomy (CARLHA): A Phase 2 Clinical Trial.
Fiche publication
Date publication
mai 2024
Journal
European urology oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LADOIRE Sylvain
Tous les auteurs :
Ah-Thiane L, Campion L, Allouache N, Meyer E, Pommier P, Mesgouez-Nebout N, Serre AA, Créhange G, Guimas V, Rio E, Sargos P, Ladoire S, Mahier Ait Oukhatar C, Supiot S
Lien Pubmed
Résumé
The relevance of next-generation hormone therapies and circulating tumor cells (CTCs) are not elucidated in biochemical recurrence after prostatectomy.
Mots clés
Abiraterone acetate, Biochemical recurrence, Biomarkers, Circulating tumor cells, Hormone therapy, Prostate bed radiotherapy, Prostate cancer, Salvage radiotherapy
Référence
Eur Urol Oncol. 2024 05 10;: